AT
Airway Therapeutics
United States · Biotech
Airway Therapeutics develops biologic drug candidates for respiratory, inflammatory and infectious diseases.
Product and customers
Its investigational zelpultide alfa is a recombinant form of human surfactant protein D. The lead program studies prevention of bronchopulmonary dysplasia in very preterm infants through a Phase 2b/3 trial. Clinical development is evaluating the candidate’s potential; it is not an established treatment.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series E-2 | $24M | Cincinnati Children's — Role not disclosed |